Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

Item

http://www.wikidata.org/entity/Q37256366

Q37256366

about

Antiretroviral therapy response among HIV-2 infected patients: a systematic review First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration Genotypic resistance profiles of HIV-2-treated patients in West Africa.Incidence of multiple Herpesvirus infection in HIV seropositive patients, a big concern for Eastern Indian scenario.Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2 An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.Importance of an Early HIV Antibody Differentiation Immunoassay for Detection of Dual Infection with HIV-1 and HIV-2 Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.Complex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.The evolution of drug resistance interpretation algorithms: ANRS, REGA and extension of resistance analysis to HIV-1 group O and HIV-2.MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.New carboxamide derivatives bearing benzenesulphonamide as a selective COX-II inhibitor: Design, synthesis and structure-activity relationship.Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection.

P2860

Q27003854-79DCE7F2-1BCC-400D-86D8-1CAF2E042834 Q33891896-5A71F7DA-5FBF-428F-A721-F2A1E5649643 Q33954546-486964A9-4E1C-40FF-982B-7035DD1BFC4F Q34016710-74042905-7D4B-45E9-AE74-9416025CB647 Q34111234-9E0ED9C6-F114-446A-9B38-D34DA4F2D484 Q34428902-8CB3A0D8-B248-45A7-A837-66FFAC39E881 Q34730950-90AE1DF4-C129-4B85-BE9C-F5206A497A43 Q34737547-78A6E691-706B-45D2-95C4-8168F9A2BE52 Q34742090-0AB31712-5CBB-422F-9C04-2F7DCBC61247 Q35083423-D9A5A7A5-6593-4490-8ECD-0C20AB6D25A8 Q35273824-B3E4E00C-3536-4E1F-BC11-1FC602B639F8 Q35770848-7B046396-B596-486D-839A-F33ED6A43000 Q35875761-69296BA9-EE3E-4A7F-99A5-9933C7A84714 Q35943486-66E2FB1C-364A-43D6-A830-344CEEBF2C87 Q36054188-43227888-AF58-4AAF-AC7F-958F65D76868 Q36564668-33DA01DA-C041-41A2-9229-8D52C5EC7087 Q37026564-FD1D11C2-9AB4-4B6C-AF0A-A4136B5B4373 Q37979703-7A0C715B-9BDF-42D0-BED6-F757B13600ED Q38755690-EFBD9955-A217-4001-8BC2-95BA0BFA3496 Q41702568-A6554E9C-83CF-4DE6-8168-7578C3970342 Q42318282-73C3C394-047E-4B92-B35F-BCC26AEBE202

P2860

Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

Item

http://www.wikidata.org/entity/Q37256366

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Virological response to highly ...... ce of drug-resistant variants.

@en

Virological response to highly ...... immunodeficiency virus type 2

@nl

type

Item

label

Virological response to highly ...... ce of drug-resistant variants.

@en

Virological response to highly ...... immunodeficiency virus type 2

@nl

prefLabel

Virological response to highly ...... ce of drug-resistant variants.

@en

Virological response to highly ...... immunodeficiency virus type 2

@nl

P1476

Virological response to highly ...... nce of drug-resistant variants

@en

P2093

Abraham Alabi

http://www.w3.org/2001/XMLSchema#string

Assan Jaye

http://www.w3.org/2001/XMLSchema#string

Guido Vanham

http://www.w3.org/2001/XMLSchema#string

Hilton Whittle

http://www.w3.org/2001/XMLSchema#string

Kevin Peterson

http://www.w3.org/2001/XMLSchema#string

Ramu Sarge-Njie

http://www.w3.org/2001/XMLSchema#string

Sarah Rowland-Jones

http://www.w3.org/2001/XMLSchema#string

Wouter Janssens

http://www.w3.org/2001/XMLSchema#string

P2860

Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2

Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

Slower heterosexual spread of HIV-2 than HIV-1.

Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.

Towards a better understanding of the epidemiology of HIV-2.

Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy

Isolation of a new human retrovirus from West African patients with AIDS.

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

P304

2200-2208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JCM.01654-08

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19420165

http://www.w3.org/2001/XMLSchema#string

P921

P932

2708512

http://www.w3.org/2001/XMLSchema#string

Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

about

P2860

P2860

Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932